COR | LOE | Recommendations |
---|---|---|
1 | B-R | 1. For patients with AF at elevated risk for stroke and CKD stage 3, treatment with warfarin or, preferably, evidence-based doses of direct thrombin or factor Xa inhibitors (Table 19) is recommended to reduce the risk of stroke.1–3 |
2a | B-NR | 2. For patients with AF at elevated risk for stroke and CKD stage 4, treatment with warfarin or labeled doses of DOACs is reasonable to reduce the risk of stroke.4,5 |
2b | B-NR | 3. For patients with AF at elevated risk for stroke and who have end-stage CKD (CrCl <15 mL/min) or are on dialysis, it might be reasonable to prescribe warfarin (INR 2.0–3.0) or an evidence-based dose of apixaban for oral anticoagulation to reduce the risk of stroke.6,7 |